Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004252 · ClinicalTrials.gov registry record · Phase 3
Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00004252 is a Phase 3 study that has completed, run by Pfizer.
The verdict
NCT00004252, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor. It is not yet known whether chemotherapy is more effective with or without SU5416 in treating metastatic colorectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of leucovorin and fluorouracil with or without SU5416 in treating patients who have metastatic colorectal cancer.
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG semaxanib
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-11 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004252
The ClinicalTrials.gov registry entry for NCT00004252 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which fluorouracil is the first listed.
NCT00004252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004252 about?
NCT00004252 is a clinical study titled "Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor. It is not yet known whether chemotherapy is more effective with or without SU5416 in treating m...
What is the current status of trial NCT00004252?
This trial is currently completed. It is a Phase 3 study. The study started on 1999-11. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00004252?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), semaxanib (DRUG).
Who is sponsoring clinical trial NCT00004252?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.